HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Slashes Guidance, Promises Sharper Focus, Bigger Innovations

This article was originally published in The Rose Sheet

Executive Summary

P&G will launch “bigger” products, pursue a more balanced growth objective, firm says during investor conference June 20, the same day the firm’s stock slipped on slashed guidance for the fourth quarter and fiscal year.

You may also be interested in...



P&G Beauty’s Sluggish 2012: The Cost Of Cutting Back?

Kline’s Nancy Mills offers perspective on P&G performance in 2012 when the company saw its market share slip in certain personal-care categories. In her blog post, Mills attributes the erosion in part to the firm’s ongoing $10 billion cost-cutting initiative, which slowed new product introductions and left some brands under-supported in a highly competitive landscape, she says.

P&G Positions Beauty Biz For Share Gains, Sustainable Growth

P&G is launching multi-benefit, first-to-market skin and hair products anticipated to drive up its U.S. beauty share, CFO Moeller says at the Barclays Back to School Conference Sept. 6. Entries will include eye care under Olay Regenerist and premium-positioned hair-care items.

P&G Defends Savings/Growth Strategy, Plans To Slash More Prices In FY 2013

P&G will roll back about $400 million of the $3.5 billion in pricing increases taken in fiscal year 2012, in an effort to include beauty and health-care products. Beauty sales declined 4% on the year, the firm reported.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel